NCT00532077已完成1 期
An Exploratory, Open Label, Multicenter Parallel Group Study to Evaluate the Effects of Single and Repeat Dosing of SB-751689 (400 mg or 100 mg) or rhPTH(1-34) on the Fractional Renal Excretion of Calcium and Phosphate in Healthy Postmenopausal Females.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 6
- 主要终点
- renal fractional clearance of calcium and phosphate
研究概览
简要总结
SB-751689 may alter calcium and phosphate handling at the kidney level. This study will examine what happens to calcium and phosphate, and other electrolytes, at the kidney after treatment with SB-751689 for 1 month. Another group of subjects will get another drug called Forteo for 1 month to compare the response of the kidney for calcium and phosphate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy postmenopausal women 40 to 65 years of age, inclusive, meeting at least one of the following: Postmenopausal defined by the STRAW criteria of 12 months of spontaneous amenorrhea with serum FSH levels = 40 mIU/mL; History of bilateral oophorectomy (with or without hysterectomy) and at least 6 weeks post-surgical with serum FSH levels = 40 mIU/mL
- •Body weight > 50 kg and BMI within the range 19 - 32 kg/m2
- •Capable of giving written informed consent
排除标准
- •Any clinically relevant biological or physical abnormality found or reported at screening which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study. These abnormalities may be identified on the screening history and physical or laboratory examination and 12-lead electrocardiogram (ECG).
- •A subject may not participate in the study if any of the following laboratory results are above the upper limit of the normal range at screening: liver function tests (ALT, AST, GGT, alkaline phosphatase, total bilirubin), plasma amylase, glucose, alkaline phosphatase, or CPK.
- •A subject may not participate in the study if any of the following laboratory results are outside the normal range at screening: serum levels of albumin-adjusted calcium, total calcium, PTH, and urinary calcium.
- •A subject with vitamin D deficiency as defined by serum 25-hydroxy vitamin D < 20 ng/mL (equivalent to 50 nmol/L) at screening may not participate in the study. A QTc interval > 450 msec at screening.
- •Positive urine drug screen.
- •Positive for HIV, hepatitis B virus or hepatitis C virus assays.
- •Urinary cotinine levels indicative of smoking.
- •History of smoking or use of nicotine containing products within one year of screening.
- •History of regular alcohol consumption
- •History of drug abuse within 6 months of the study.
- •Participation in a study with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, calcium containing antacids, aspirin or nonsteroidal anti-inflammatory drugs, vitamins, herbal and dietary supplements, excluding study related vitamin D and calcium supplements, within 14 days prior to the first dose of study medication.
- •Donation of blood in excess of 500 mL within 56 days prior to dosing.
- •Evidence of hepatic or biliary disease (including cholecystectomy and Gilbert's Syndrome).
- •Significant renal disease as define by:
- •Serum creatinine clearance <60ml/min (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):
- •A validated web-based calculator is found at: http://nephron.com/cgi-bin/MDRDSIdefault.cgi
- •GFR Calculator
- •To calculate estimated GFR (mL/min/1.73m2) manually:
- •= 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if African-American)
- •= exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African American))
- •Urine protein/creatinine (mg/mg) ratio >2.5; or urine albumin concentration > 300 ug/mg.
- •Known loss of kidney, either surgically or by injury or disease
- •History of significant gastrointestinal
- •History of a gastrointestinal surgical procedure that might affect the absorption of SB-751689
- •History of sensitivity to any of the study medications or components thereof.
- •History of clinically significant cardiovascular disease.
- •History of pancreatitis or kidney stones. Medical conditions which might alter bone metabolism
- •Subjects at increased risk of osteosarcoma such as those with Paget's disease of the bone or any prior external beam or implant radiation therapy involving the skeleton.
结局指标
主要结局
renal fractional clearance of calcium and phosphate
时间窗: over 1 month
次要结局
- renal fraction clearance of electrolytes, cAMP, safety measures, and serum biomarkers(over 1 month)
- urinary excretion of sodium, magnesium, potassium, bicarbonate, and chloride
- Albumin-adjusted serum calcium levels
- Vitamin D and P1NP levels
- Plasma levels of SB-751689 and rhPTH(1-34)
- Plasma PTH
- Adverse event reports, 12-lead ECGs, vital signs, nursing/physician observation and laboratory tests.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal FunctionPneumoniaNCT00759564Pfizer29
已完成
1 期
Pharmacokinetic Study of Aztreonam-Avibactam in Severe Renal ImpairmentRenal InsufficiencyNCT04486625Pfizer11
已完成
4 期
Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant RecipientsKidney TransplantationNCT00121810Hoffmann-La Roche305
已完成
1 期
A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954Renal ImpairmentHealthy VolunteersNCT03296787Takeda32
已完成
1 期
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218Renal ImpairmentNCT05844228Vir Biotechnology, Inc.28